text:
Q: run a jdk1.4 compiled jar on jdk1.6 I want to run a jdk1.4 compiled jar on jdk1.6.
Will there be anything wrong about it.
JVM is forward compatible, so I think there will be no problem.
Is it true.

A: As of the Java byte code, the compiled code should be backward compatible with increasing JRE versions. This means that in general, a v6 JVM should be able to run code that is compiled with a v4 JDK. (While the JRE is backward compatible, the Java compiler is forward compatible, i.e. v4 source code is supposed to be compilable by a v6 compiler.)
However, you can run into problems with the libraries that the v4 code is compiled against when the code is run on a v6 JRE. You can find an overview of API changes from v4 to v6 on this webpage.

redpajama_set_name: RedPajamaStackExchange


text:
COVID-19 testing for asymptomatic arrivals from Philippines to be cancelled starting from September 24; arrivals to undergo quarantine at group quarantine facility and to be tested before completing quarantine
On September 23, the Central Epidemic Command Center (CECC) announced changes to the quarantine measure imposed on all travelers arriving in Taiwan from the Philippines. In consideration of the status of the pandemic and risk of infection in the Philippines, characteristics of COVID-19, and effectiveness of testing among asymptomatic arrivals from the country, after consulting related experts, the CECC has made modifications to the quarantine measure for arrivals from the Philippines, effective from September 24. Details about the measure are listed below.
1. Travelers with symptoms must have their specimens collected at the airport upon arrival in Taiwan, and collecting specimens from travelers with no symptoms is cancelled. All travelers arriving from the Philippines must undergo quarantine at a group quarantine facility after entry and will be tested for COVID-19 before the end of the quarantine period.
2. Foreign nationals without an Alien Resident Certificate or a resident visa must provide a certificate of a negative COVID-19 test result issued within three days of boarding before they are allowed to board their transit flight or enter Taiwan.
3. Foreign nationals, except those holding an Alien Resident Certificate or a resident visa, are required to pay NT$ 1,500 per night for their stay at a group quarantine facility.

redpajama_set_name: RedPajamaCommonCrawl


50 Stylish Bedroom Decorating Ideas Design Tips For Modern Bedrooms Elegant Home Plans. Bedroom Decor Ideas Stylish Bedroom Decorating Ideas Bedroom Cool House Design. 175 Stylish Bedroom Decorating Ideas Design Pictures Of Inspiring House Design. 175 Stylish Bedroom Decorating Ideas Design Pictures Of Beautiful Home Plans. 175 Stylish Bedroom Decorating Ideas Design Pictures Of Elegant House Ideas. 175 Stylish Bedroom Decorating Ideas Design Pictures Of Inspiring Home Ideas. Beautiful Bedroom Decorating Ideas Bedroom Design Decorating Ideas Luxury Home Ideas. 25 Best Ideas About Beautiful Bedrooms On Pinterest Beautiful Impressive House Plans. Beautiful Bedroom Decorating Ideas Elegant House Ideas. 175 Stylish Bedroom Decorating Ideas Design Pictures Of New House Plans. 25 Beautiful Bedrooms With Accent Walls 6 Beautiful Bedrooms Luxury House Design. 25 Best Ideas About Beautiful Bedrooms On Pinterest Beautiful Luxury Home Plans. 25 Best Ideas About Beautiful Bedrooms On Pinterest Beautiful Inspiring Home Plans. Beautiful Bedroom Decorating Ideas Awesome Home Plans. 175 Stylish Bedroom Decorating Ideas Design Pictures Of Beautiful Home Design. Fabulous Beautiful Bedroom Decor Entrancing Nice Bedroom Designs Modern House Design. New Home Bedroom Designs Bedroom Awesome Home Design For You Cheap Home Ideas. 175 Stylish Bedroom Decorating Ideas Design Pictures Of Beautiful Best Home Ideas. Beautiful Rooms Interior Design Beautiful Bedroom Interiors Dact Unique House Design. 17 Best Images About Beautiful Wall Decoration In The Bedroom On Cheap House Plans. 175 Stylish Bedroom Decorating Ideas Design Pictures Of New House Plans. Bedroom Modern Beautiful Bedrooms Decor In 2017 Beautiful Cheap Home Design. Pretty Bedroom Decor Ewan Furniture Modern House Plans. 25 Best Bedroom Decorating Ideas On Pinterest Rustic Room Cheap House Plans.
Beautiful Bedroom Decor Ideas, Beautiful Bedroom Decoration Games, Beautiful Bedroom Design Images, Beautiful Bedroom Ideas Tumblr, Beautiful Bedroom Ideas Uk, Beautiful Bedroom Wall Ideas, Beautiful Master Bedroom Decor, Beautiful Room Decor Photos, Beautiful Room Decoration Games, Pretty Bedroom Wall Decor.


A Cost Per Action (CPA) affiliate network which lets you offer hundreds of offers to your readers. Most programs pay per lead or per sale.
TLA is the most popular place on the net to buy and sell text links. You can also sell in content text links too.
Kontera is an in-text advertising service which lets you place PPC ads within your content.
BidVertiser lets you add text ads to your blog. You are paid on a per click basis.
Adsense is the most used advertising network in the world. You can display text or banner ads on your blog. You can also add your adsense code to your youtube videos.
Netklix is a text based PPC network. You can choose the type of ads that appear on your site and Netklix offer all major ad formats.
SocialSpark offers bloggers a variety of ways to make money through their blog. You can review products, websites and services and you can display sponsors ads on a per day basis.
LinkXL lets you sell a maximum of 10 links on individual pages on your blog. You can set the price according to PageRank and you have an option of using nofollow as well.
Sponsored Reviews is a marketplace which lets you see paid reviews on your blog.
The PepperJam ad network have a wide range of merchants for you to choose from. Most companies per on a CPA or revenue share basis.
Performancing is a banner ad marketplace which is very popular with bloggers. Bloggers are paid 60% of the ad sales they generate.
An advertisement marketplace which is popular with some bloggers. You can sell banner ads, text links and peel away ads.
Brought to you by the same people as Text Link Ads, ReviewMe is a marketplace for paid reviews. You can let ReviewMe determine your review rate or you can set your own price.
Similar to Performancing, BuySellAds lets you sell banner ads directly on your blog. They mainly concentrate on 125×125 pixel banner ads.
LinkWorth have a wide range of ways for you to make money through your blog including text and banner ad sales, in text advertising and paid reviews.


text:
Deploying their immense wealth, business and tech impresarios are investing
in their next disruption
Anti-aging research is the next big thing in healthcare. Companies such as Calico and Human Longevity, both based in California, are pioneering genetic and pharmacological techniques to reduce the ravages of time on the human body. At the fringes of science, Alcor, an Arizona-based nonprofit, vitrifies dead people in hopes of reviving them at a later date, while Russian internet mogul Dmitry Itskov seeks to create cybernetic bodies to host human consciousness.
Aging "is one of the great mysteries of biology," says Dr. Thomas Rando, director of the Glenn Center for the Biology of Aging at Stanford University. "If we begin to understand what the process of decline associated with aging is, and if we can slow that by targeting those mechanisms, then potentially one could alter its course."
The idea that death can be forestalled by a magical substance, usually the mystical waters of the Fountain of Youth, dates back at least to the Greek historian Herodotus in the 5th century BC. The "elixir of life" also appears in ancient Chinese and Indian legends and in alchemical texts from medieval Europe. The Spanish explorer Juan Ponce de León was thought to have quested throughout the New World in the 16th century in search of the fabled Fountain of Youth.
As living standards improved in the 20th century, the quest for eternal life was subsumed into modern medicine's fight against infectious disease. The average American's life expectancy rose from 70 in 1960 to almost 79 in 2012, according to the World Bank. Yet little attention was paid to extending good health into old age. Rather than dying at 70, people now live to be far older, but often with a lesser quality of life.
Serious anti-aging research only started about a decade ago. "Improving health is the goal, and longevity might be the consequence of the improvement," says Dr. Joon Yun, president of hedge fund Palo Alto Investors and sponsor of the Palo Alto Longevity Prize, which funds anti-aging research.
At the time, scientists interested in treating or preventing the impairments of aging were often seen as either out of touch or just plain kooky. "I remember talking to some people from [the healthcare company] Roche about 15 years ago about this notion of drugs that might target the aging process," Rando says. "They thought that was ridiculous."
Two trends have since proved to be the foundation for longevity research: new discoveries in genomics and the ability to share information over the internet. But for the most part, longevity research has not been funded by conventional research institutes or biotech companies—as great as the payoff could be, there's little to no short-term return. Instead, some of the world's wealthiest and most visible entrepreneurs have taken up the challenge. Some have a background in medicine, but most of these investors come from the worlds of technology and engineering. That makes more than just financial sense. "It's clear now that biology is an engineering project, whereas before that wasn't so obvious," says Sonia Arrison, author of 100 Plus, a book about the effects of superannuation.
The prospects are encouraging: Participants in longevity research say they expect rapid gains in a matter of years and decades. It's not unreasonable to think that today's children could regularly crack 100 or even 120.
"It's the holy grail of healthcare, extending a human lifespan," says Dr. Peter Diamandis, cofounder of Human Longevity and CEO of the XPrize Foundation, which awards financial gifts for scientific and technological advancements. Yet there's a downside to the prospect of extreme longevity: If people don't maintain good health into their senescence, longevity could place enormous strain on economies and societies.
And, of course, philosophical questions abound. What do highly successful people like Sergey Brin, Larry Ellison or Peter Thiel—or anyone else for that matter—gain by living a few years more? How will added longevity change age-old notions of the phases of life? Will longevity become, even more than it already is, a gift largely conferred on the wealthy?
The research will not pause to answer these questions. Here are six successful entrepreneurs who have turned their energy—and their wealth—to the project of longer life.
DR. JOON YUN
Managing partner and president,
Palo Alto Investors Sponsor, Palo Alto Longevity Prize
"Nature endowed the greatest healthcare system in the world: It's called our bodies," Yun says, explaining why he endowed the $1 million Palo Alto Longevity Prize. "Our body is an incredible system that is able to self-heal." Yet beginning in middle age, "it is more vulnerable to the slings and arrows of life."
Yun, 47, graduated from Harvard with a degree in evolutionary biology before getting his MD at Duke and joining Stanford's clinical faculty. He signed on with Palo Alto Investors, a $1 billion healthcare investment fund, in 1998. His goal? To extend what he calls "healthspan"—our healthy years before we begin to decline—into middle and old age; if longer life is a consequence, so much the better.
Under the current healthcare regime, Yun says, "we have been helping people live longer and stronger lives, but the trajectory is unsustainable. This idea of helping people live longer without solving the underlying cause of aging lends itself to exponential increases in healthcare spending.
"This is an area of relative market dysfunction," he adds. Biotech companies and healthcare providers are incentivized to treat diseases, not prevent them. Compounding the problem, increased healthspan is hard to measure; it requires long time spans, discouraging companies with short-term goals from pursuing it.
Yun created the Longevity Prize to incentivize research in two areas: restoration of the body's ability to repair and maintain itself, and extending the lifespan of a mammal by 50 percent. Preventing people from getting sick as they age, Yun says, is about "getting a lot more healthcare value for a lot less money."
DMITRY ITSKOV
Founder, New Media Stars, 2045 Initiative
Itskov's Facebook page displays a piece of promotional art from James Cameron's 2009 movie, Avatar, with Itskov's face pasted over it. The movie was about futuristic soldiers who transfer their minds to artificial bodies. Itskov, who launched Russian internet company New Media Stars in 1999, must have really liked Avatar, because in 2011 he founded the 2045 Initiative, a foundation that aims to transfer human consciousness into cybernetic bodies.
Itskov, 34, has plotted the evolution of humanity from carbon-based life form to liberated machine sentience. By 2020, according to his website, he foresees the "widespread use of affordable android 'avatars' controlled by a 'brain-computer' interface." By 2025, an "autonomous life-support system for the human brain linked to a robot 'avatar' will save people whose body is completely worn out." By 2045, "substance-independent minds will receive new bodies with capacities far exceeding those of ordinary humans."
To get there, Itskov is investing in startups creating avatar technology, while the 2045 Initiative is designed to coordinate and support scientific advancement in the field.
Cofounder, Google backer, Calico
On January 14, 2013, Brin posted on his Google+ page a photo of jellyfish suspended in the limpid water of a lake in Palau; because some jellyfish do not appear to die, they have become a focus of aging research. "No place in the world has made me consider my place in the universe like Jellyfish Lake," Brin wrote. "Millions of creatures all drifting seemingly aimlessly, searching for light, for the energy to spawn so generations of their offspring may do the same years later. I take a small breath, sink toward the bottom, watching them in wonder and think, are we really so different?"
This kind of thinking led Brin and Larry Page, his Google cofounder, to launch Calico in 2013 with money from the company's venture capital arm, Google Ventures. (Brin is said to be considerably more involved. One possible reason why: Brin, 41, has a genetic mutation, LRRK2, which is thought to substantially increase the probability of developing Parkinson's disease.) Calico's stated goal is "to harness advanced technologies to increase our understanding of the biology that controls lifespan." The company announced a $1.5 billion coinvestment with pharmaceutical company AbbVie in September 2014 to construct an R&D lab "focused on aging and age-related diseases, including neurodegeneration and cancer."
Calico's approach is twofold. In the short term, the company is developing drugs to treat age-related diseases; in the long run, Calico hopes to gain a larger, more holistic understanding of why humans age and to fight aging using pharmacology.
Calico is in a "unique situation in being able to invest in basic aging research without having to turn a profit for a long time," Stanford's Rando says. "So there's the potential there to do something really big."
Executive chairman and CTO, Oracle
Founder, Ellison medical Foundation
Ellison, one of the most intriguing figures in Silicon Valley, gave more than $350 million for anti-aging research from 1997 to 2015, making him by far one of the largest sponsors of the field. With no tangible results in sight, he stopped making new grants in 2013, and has never publicly explained why. The foundation, however, still operates.
When Ellison, now 70, established the foundation, "there wasn't enough traction to allow any success in the field," says Dr. Kevin Lee, executive director of the Ellison Medical Foundation. The research grants provided by the foundation subsequently "defined this as a problem that wasn't being addressed." Ellison's support, Lee says, helped move anti-aging research from the scientific fringe to the mainstream. "The foundation's timing was perfect in providing the seeding for this field to develop."
Director of engineering, Google cofounder, Singularity University
Kurzweil is the eccentric uncle of Silicon Valley. He invented the CCD flatbed scanner and a machine that reads text to the blind. The recipient of 20 honorary doctorates, he cofounded Singularity University in Silicon Valley in 2007. Its mission: to become the epicenter of theorizing about the "singularity," the moment when artificial intelligence will surpass human minds, allegedly leading to a tech utopia. Kurzweil believes that anti-aging research, nutrition and nanotechnology, among other things, will "enable humans to live indefinitely," according to a note he wrote for the Methuselah Foundation website.
A major donor to the research-oriented Methuselah Foundation, Kurzweil, 67, is also a member of the Alcor Life Extension Foundation, a nonprofit that cryonically preserves people when they die in the hope of one day bringing them back to life.
"What's the harm in rationalizing death?" Kurzweil wrote in 2004. "The harm is that in rationalizing something that is tragic, we fail to take the urgent action needed to avoid the tragedy." As human lifespans grow, Kurzweil adds, "we are also going to merge with our technology and expand our cognitive and emotional capabilities, as well as the depth and richness of our intellectual, relational, artistic, sexual and emotional experiences many-fold."
Cofounder, PayPal, Palantir Technologies
Backer, SENS Research Foundation, the Methuselah Foundation
There are three approaches to death, Thiel recently told the Guardian: "You can accept it, you can deny it or you can fight it. I think our society is dominated by people who are into denial or acceptance, and I prefer to fight it."
Thiel, 47, has said that he plans to live to be 120. He runs, takes human growth hormone, adheres to a Paleo diet and eschews sugar. He has also donated at least $6 million to the SENS Research Foundation and the Methuselah Foundation, both longevity-research projects started by a Cambridge-educated biologist named Aubrey de Grey.
"There's 100,000 people or more dying every single day of aging or age-related causes," de Grey says. "Mostly dying after a long period of decline and dependence and disease and general misery. So, you know, every single day that I bring the defeat of aging forward—which I probably do about once a month—I'm saving 100,000 lives. That's pretty motivating."
Thiel said in a Reddit "Ask Me Anything" session last year that he prefers to invest in medical and research ventures when they resemble "software companies—a group of really committed founders with a clear vision of what they're trying to do."
"The key thing about Peter Thiel is he has a high threshold of reputation tolerance," the Methuselah Foundation's CEO, David Gobel, says. "There is a very large number of millionaires and billionaires who are legitimately terrified of being pilloried and burned at the stake in the media, because it's happened to them and it has consequences… I think he's made a rational calculation that his reputation is not worth as much as the potential."
TWO APPROACHES
Some longevity organizations focus on bringing people back to life, others on keeping you from dying in the first place.
HUMAN LONGEVITY, INC.
A collaboration between cofounders Dr. Peter Diamandis, Dr. Robert Hariri and pioneering geneticist Dr. Craig Venter (see Q&A with Craig Venter), HLI may be the only serious competitor to Google Ventures' Calico. The company focuses on extending life through genomics and stem cell therapies, and specifically targets cardiovascular and neurodegenerative diseases and cancer.
HLI is "building the largest genome-sequencing facility on the planet," Diamandis says. It will also compile microbiome, MRI and metabolism data. "It's just a massive amount of data that would have been impossible to manipulate, fathom or mine even just five years ago," Diamandis adds. "We're targeting millions of data sets from millions of individuals from around the world, from across ages, from across disease groups and mining that to extract knowledge and information."
In January, the company announced a gene-sequencing agreement with biotech giant Genentech, which hopes to use Human Longevity's findings to speed the discovery of new drugs.
ALCOR LIFE EXTENSION FOUNDATION
Alcor vitrifies people after they die in the hopes of bringing them back to life in the future. Members' bodies are infused with a "cryoprotective solution, a kind of medical antifreeze" after they die, Alcor CEO Max More says, before being cooled and stored in liquid nitrogen.
The cost? At least $200,000 for the entire body or $80,000 for just the brain, and it can be paid using life insurance benefits. According to More, many wealthy members set up a trust so they have a nest egg if and when they wake up.
← JOON YUN, M.D.
The Scientific Quest to Cure Aging →


As many of you know, I got back from a visit to the Crystal Bridges Museum in Bentonville, Arkansas last week and my. mind. is. blown. Y'all, it is gorgeous and amazing!
I had such a good time touring the museum and seeing works from artists that I've heard about my whole life. Plus, being up close and personal with the actual artwork that most of us have only seen in history books or on TV? My heart is still beating.
But, man, I will admit that I spent the entire thinking to myself that I wished my husband and kids and been with me. They would have loved the museum so much and, since Crystal Bridges is SO family friendly, it would have been so easy to have them with me.
If you're planning a future visit to the museum with your crew, then let me share with you my six must haves when visiting Crystal Bridges Museum with kids.
Hand Wipes: Dirt, oils, and debris are a death sentence to art. Yes, I know that you're not going to let your kids touch the art (it's not that kind of museum) but hey, accidents happen.
So, I recommend bringing along some of these wipes and taking a moment every now and then to quickly clean little hands. Just in case.
A Small Crossbody Bag: So, big bags (like diaper bags, backpacks, and totes) are not allowed in the museum gallery areas. There are free lockers in the downstairs area where you can stash those things.
However, you will probably want to keep a couple of items on hand so plan to pack a small crossbody bag for them. Why a crossbody? Because it's customary to wear your bag in front of you when visiting a museum (to avoid backing into or knocking down the art).
Water Bottle: Perfect for when you're hanging out in the lobby areas or walking any of the gorgeous nature trails. Food and drink ARE NOT allowed in the galleries and the museum has a great coffee bar and restaurant on site. But! We all know how kids are so bring a water bottle.
Stroller: The museum and it's surrounding nature trails are HUGE. While I'm not sure if strollers are allowed on the gallery floors, bringing one to navigate everything from the parking lot, to the lobby areas, to the trails is a good plan.
There are roomy elevators and wide hallway with double doors or arches so navigating even a large side-by-side stroller shouldn't be an issue. But yeah, DEFINITELY bring a stroller if you've got very young kids.
Sunscreen: You'll want to bring some sunscreen to lather up your kids while walking the nature trails but I also highly recommend putting some on while in the museum itself. Yes, I really do.
See, the museum features spectacular architecture with lots and lots of soaring windows and skylights. It allows you to enjoy the calming nature that surrounds the museum but will mean that the more sensitive skinned among us (like my little guy, Finn) will need to wear some sunscreen – just in case.
Tablet: Yes, you are there for the art and nature but did you know that the museum has an interactive app? Yep, it does and allows users to enjoy the juxtaposition of mixed medium art with modern technology.
There's a 360 VR tour, more information about the artists, and some great history lessons, too. Since kids are so comfortable with using devices, handing them a tablet with the museum's app queued up can actually make your visit more enjoyable.


This post originally appeared on The Georgetown Voice.
I don't know if it was my obsession with watching Pokémon or all the long nights I spent reading fantasy novels, but I've always had an insatiable thirst for adventure and exploring the unknown. One day, I swore to myself, I would save enough money and travel the world, sampling exotic new foods and forging exciting new friendships. When I became old enough to realize I was undocumented, however, I discovered I would never be able to leave the country without giving up my right to return, even though the U.S. has been my "home" since I arrived as a four-month old infant. Reluctantly and brokenheartedly, I set aside my childhood dreams and traded them for harsher realities.
When Obama created the DACA (Deferred Action for Childhood Arrivals) program via executive action in 2012, so many doors were opened for me and countless other undocumented youth across the nation. Although DACA does not create a pathway to citizenship, it provides a renewable working permit and temporary relief from deportation. After talking to a wonderful fellow undocumented Georgetown student, I learned that DACA also permitted international travel (though only in certain circumstances) via Advance Parole, a special travel document that DACA recipients can obtain to re-enter the U.S.
Obtaining Advance Parole, however, is a ridiculously lengthy, expensive, and frustrating process. After paying a non-refundable $360 application fee, applicants must wait up to four months for approval by the Department of Homeland Security. Even upon approval, Advance Parole cannot 100 percent guarantee re-entry into the U.S. At any given border crossing or checkpoint, DACA recipients can still be denied admission into the country by Customs & Border Protection Agents, which can make traveling abroad a very risky ordeal.
With support from the Georgetown Scholarship Program and pro-bono assistance from an attorney, I was able to leave the U.S. for the first time last summer. I first traveled to Nicaragua to participate in the GU Impacts Program, but afterwards, I was finally able to return to Indonesia for the first time in 20 years, where I met long-lost family members, explored a country I had only known through stories, and reconnected to my roots. Although my journey back to the U.S. was incredibly nerve-racking, I was fortunately able to come home without any legal hiccups.
When I was nominated by Georgetown to study abroad in Budapest, Hungary last semester, I applied for Advance Parole a second time. But when December rolled around and my Advance Parole had not arrived yet, I lost nearly all hope that it would ever come. Thankfully, I received notice that it was approved on Dec. 23, which turned out to be the best early Christmas present I could've ever asked for.
Despite all the legal complications and the possibility of not being able to return, I decided that the benefits of traveling abroad were well worth the risks.
First of all, my status as a DACA recipient only allows me to leave and re-enter the U.S. for educational, humanitarian, or employment purposes. This means that once I graduate from Georgetown, it might be several long years before I get another chance to see the world, especially if the DACA program ends once Obama's term is over—a very real possibility if the Republicans take over the White House.
Second, I must admit that I chose to study abroad so I could temporarily escape the daily struggles of being undocumented in America. Living in a country where I am repeatedly told I am unwelcome and where thousands of politicians are constantly scheming to deport me is psychologically and emotionally draining. Furthermore, realizing that I cannot individually "fix" my undocumented status and change the circumstances I was born into has been an extremely frustrating reality to accept. I've lived in the U.S. for over 20 years, graduated as the salutatorian of my high school, paid countless dollars in taxes, and am set to graduate from Georgetown in a year—but regardless of what I do, or how many selfies I take with the Vice President, I don't know if I'll ever be "American" enough for the U.S. government.
Here in Hungary, my student residence permit ironically gives me more legal rights than I have in the United States, though my undocumented identity has still managed to define my study abroad experience. I am spending my time in Europe as if it is the only chance I will ever get to see it—because realistically, it very well might be. Most weekends, I find myself traveling to other countries, not because I hate it here (Budapest is an amazing city in its own right), but because the ability to cross international borders freely and without worry is an exhilarating privilege that I've only ever dreamt of.
For months, I've entertained the idea of permanently moving to another country to escape my immigration troubles, but spending so much time abroad has shown me that this option just isn't for me. All the people I love and all the issues I care about are in the United States, and my lack of "proper" documentation does not make me any less of an American. While I hope to continue exploring the world in the future, the United States will always be my home, and I refuse to give that up without a fight.
Previous PostArtist Remembers His Fallen Friend the Way He Knows How.


ISLAMABAD: The World Bank has lowered the 2,160-megawatt Dasu hydropower project's rating to 'moderately unsatisfactory' after Pakistan could not resolve outstanding issues in the past over two years, which will now push the completion period beyond 2021.
It was the second downward revision in the project's implementation rating over the past two and a half years, indicating the systemic bureaucratic weaknesses that have started affecting strategic projects. Last time, the World Bank had cut the progress rating to moderately satisfactory in June 2016.
The previous federal government had failed to resolve a host of land-related issues and could not ensure safety measures, leading to casualties. "The implementation progress of the DHP-I has remained slower than expected," said the latest implementation status report of the World Bank-funded project, released in the outgoing week.
The report noted that land acquisition has only reached 742 acres, out of the 1,987 acres required for construction areas. The accrued delay during the last two years in acquiring land has now reached a stage where it directly affects the pace of the main works construction, and implementation progress has, therefore, been set to be moderately unsatisfactory, stated the report.
Pakistan had envisaged completing the project by December 2021 to add 2,160MW of electricity to the national grid under the first phase. The previous government preferred the 4,320MW Dasu hydropower project over Diamer-Bhasha dam and then prime minister Nawaz Sharif was initially keen to inaugurate its first phase before the end of his five-year term in 2018.
The World Bank financing is also important for the timely completion of the project's first phase, which has a total cost of $4.3 billion. The bank has already approved $588.4 million for the scheme. It has also given guarantees of $460 million for raising about $2.5 billion in commercial loans from domestic and foreign lenders. Owing to the slow physical progress, the World Bank released only $179 million or 30.4% of its loan component in the past four years, according to a project progress report of the lender.


A dead battery is the most common reason vehicle breakdown services are needed. A vehicle battery can go dead for a variety of reasons, such as leaving on lights and using excessive electronic accessories before the battery is fully charged. However, it can also die for no apparent reason; that's when you probably will need to replace it, which can be inconvenient and expensive. There are steps you can take to ensure your battery's health and longevity. Unless you live in an extreme climate which shortens battery life, your vehicle battery should last three to five years. Follow the basic maintenance tips below to ensure your battery works for as long as possible.
The terminals and clamps on a vehicle battery are especially prone to corrosion, so inspect them regularly. Corrosion build-up can cause the battery to malfunction, as electrical charge can no longer pass between the battery and the cables. If you notice corrosion around the terminals, gently scrape it off with some pliers. The casing should also be regularly inspected for cracks or other signs of damage and is usually part of any service appointment.
Frequent short journeys place stress on your battery and shortens its lifespan. The alternator charges your battery when you drive the vehicle, and when you frequently drive short distances, the alternator doesn't get time to charge the battery properly. Try to avoid short journeys whenever possible, especially in cold climates.
If you don't use your vehicle often, you'll find your battery prone to dying, especially in colder months. Before buying a charger, you'll need to know what sort of battery your vehicle has. If your vehicle has start-stop technology, you'll need a smart charger. Consult with your dealership's Service Department if you are unsure.
If you are required to disconnect the battery for any reason always refer to the vehicle's manual for the correct procedure. On the majority of vehicles, the negative terminal is disconnected first, followed by the positive terminal (vice-versa to reconnect them.) However, this can vary in some models, so check first. There may also be certain procedures required to reset on-board computers and seat positions following removal of the battery, so you will need to be familiar with the security codes.
• The case looks swollen, the sides are bulging outwards, or if fluid is leaking from the battery. Don't operate the vehicle; call your dealership for advice and replace the battery as soon as possible.
When you replace the battery, ensure you dispose of it in an environmentally responsible manner; a vehicle battery is a dangerous item if disposed of in the wrong way. The best course of action is to have the dealership replace the battery for you whenever possible. Battery acid is extremely corrosive and dangerous.
Vehicle batteries aren't designed to last forever, but with some basic knowledge and maintenance you can ensure yours runs reliably for as long as possible. Developing good habits such as avoiding short journeys and turning all the electronics off before switching the engine off will reduce stress on the battery and lessen the chance of your battery going dead when you least expect it. If you've had your battery for a couple of years, have it checked during your next regularly scheduled maintenance check to ensure it's still functioning as it should be.


text:
package com.tumblr.cardboard;

import android.content.Intent;
import android.support.v7.app.AppCompatActivity;
import android.os.Bundle;
import android.text.TextUtils;
import android.view.View;
import android.widget.Button;
import android.widget.EditText;

public class SearchActivity extends AppCompatActivity {

	@Override
	protected void onCreate(Bundle savedInstanceState) {
		super.onCreate(savedInstanceState);
		setContentView(R.layout.activity_search);

		final EditText editText = (EditText) findViewById(R.id.search_term);
		final Button button = (Button) findViewById(R.id.start);

		editText.setText("cat gifs");

		button.setOnClickListener(new View.OnClickListener() {
			@Override
			public void onClick(final View v) {
				if (!TextUtils.isEmpty(editText.getText())) {
					Intent intent = new Intent(v.getContext(), Tumblr3DActivity.class);
					intent.putExtra(Tumblr3DActivity.EXTRA_SEARCH_TERM, editText.getText().toString());
					SearchActivity.this.startActivity(intent);
				}
			}
		});
	}
}

redpajama_set_name: RedPajamaGithub


It was April 14, 1960; at the Albany Mennonite Church that Drift Creek Camp was birthed. Building on a heritage of youth camping that began when the Portland Mission took inner city children out of the city for a rural experience, camping as an activity of the Mennonite Church was formally organized. From that April meeting grew the Mennonite Camp Association, Inc., Drift Creek Camp's parent organization.
It was largely a lay movement; like much of early Mennonite camping and retreating, in this case a membership organization. Dues for entering were $500.00 for a life membership or $100.00 for an annual. These dues paid for materials and most labor was voluntary. In the years leading up to the development of DCC, various camps had been conducted using rented facilities such as White Branch Camp. That limited the ability of Oregon Mennonites to have the scope and quality of camping that was desired. So after considering several sites, the oval on Drift Creek was chosen as the place. Here nature's beauty could lead the users in an experience with God's word in a setting that would enhance the experience with the Author of both the Word and the natural setting, and the common experience that comes from drawing apart in God's presence.
Clearing of brush and trees to construct an access road began July 4, 1961, by a group from Albany and Sweet Home Mennonite churches. After three years of land clearing, creek bridging, road grading, and building construction, Drift Creek Camp was ready for real camping. So in the summer of 1964 the first summer youth camp was conducted. Facilities were primitive; a pole building combined as kitchen, dining hall and meeting room. Rustic tents were the main housing.
In the following years, six a-frame dormitories were built for lodging, but the last and largest of the A-frames was the main lodge, constructed during the years 1967-69, with kitchen, dining, recreation, lounge room and offices on first floor, and chapel and lodging for about 90 on second and third floors.
Other buildings constructed over the years were a caretakers' cabin, cooks' quarters and the major addition of the Activities Center for undercover recreation in 1993.
Program wise, the camp grew from its beginnings as a summer youth camp operated by the Association to a major Conference Center with organizations renting the facilities for much of the summer weeks and groups on most weekends for the remainder of the year.
The recent addition of the Drift Creek Nature Center with a separate Advisory Board under the MCA Board is the newest endeavor of the membership to take advantage of the unique natural environment of Drift Creek Camp. A new chapter in the life and ministry of Drift Creek Camp and Conference Center and the Nature Center is just beginning!


text:
/**
 *
 */
package lebah.listeners;

import java.io.FileOutputStream;
import java.io.IOException;
import java.io.PrintStream;
import java.text.SimpleDateFormat;
import java.util.Date;
import java.util.logging.FileHandler;
import java.util.logging.Logger;
import java.util.logging.SimpleFormatter;

import javax.servlet.http.HttpServletRequest;

/**
 * @author Shamsul Bahrin bin Abd Mutalib
 *
 */
public class LoginLogger {

	static {
		try {
			String workingDir = System.getProperty("user.dir");
			FileOutputStream os = new FileOutputStream(workingDir + "/lebah.login." + new SimpleDateFormat("ddMMyyyy").format(new Date()) + ".log");
			System.setErr(new PrintStream(os));
		} catch ( Exception e ) {
			e.printStackTrace();
		}
	}

	public static void log(HttpServletRequest req, String userName, boolean success) {

		try {
			String uri = req.getRequestURI();
			String s1 = uri.substring(1);
			String appname =  s1.substring(0, s1.indexOf("/"));

			String remoteAddr = appname + ", " + req.getRemoteAddr();
			String logDate = new SimpleDateFormat("dd-MM-yyyy hh:mm a").format(new Date());

			System.err.println(logDate + ": " + remoteAddr + ", " + userName + ", " + success);

		} catch ( Exception e ) {
			e.printStackTrace();
		}
	}

}


text:
About Us History Our Values Code of Practice Chairman's Message Executive Management Team Media
Executive Search Leadership Advisory
Consumer, Retail and Services Energy and Natural Resources Financial Services Healthcare and Life Sciences Technology and Communications Government and Not for Profit Industrial and Manufacturing
Board and CEO Services Financial Officers Information Technology Officers
Digital Education Payments, Digital and Transaction Services
Belgium Czech Republic Denmark Finland France Germany Italy Netherlands Norway Poland Portugal Spain Sweden Switzerland Turkey Ukraine United Kingdom
UAE Saudi Arabia
China Hong Kong India Japan Singapore Thailand
Canada Mexico USA Argentina Chile Colombia Peru
Home Insights Pharmaceutical Sector Update – November 2020
Pharmaceutical Sector Update – November 2020
CURRENT DEVELOPMENTS – GLOBAL
J&J Covid-19 Vaccine candidate yields strong immune response in early trial
A single dose of Johnson & Johnson's experimental COVID-19 vaccine produced a strong immune response against the novel coronavirus in an early-to-mid stage clinical trial. The vaccine, called Ad26.COV2.S was equally well-tolerated at two different doses.
However, it is unclear whether elderly people, one of the populations most at risk from the virus, will be protected to the same degree as younger people with the J&J vaccine. The trial in close to 1,000 healthy adults, which is backed by the US government, began after the J&J vaccine was found in July 2020 to offer strong protection in a single dose to monkeys.
Phase III trials of Astrazeneca Covid-19 Vaccine candidate begins in US
AstraZeneca said it has begun enrolling adults for a US-funded, 30,000-subject late-stage study of its high profile COVID-19 vaccine candidate. Trial participants will receive either two doses of the experimental vaccine, dubbed AZD1222, four weeks apart, or a placebo.
The trial is being conducted under the US government's Operation Warp Speed program, which aims to accelerate development, manufacturing and distribution of vaccines and treatments for COVID-19.
Bacterial viperins prove effective against human viruses: researchers
Virus-fighting viperins, part of the human immune system, turn out to have bacterial counterparts that might boost the fight against human disease. By tracking the evolution of what may be our oldest means of fighting off viral infection, a group at the Weizmann Institute of Science has uncovered antiviral substances that may lead to the development of highly effective antiviral drugs.
These substances are made by virus-fighting enzymes known as viperins, which were previously known to exist only in mammals, and have now been found in bacteria. The molecules produced by the bacterial viperins are currently undergoing testing against human viruses such as the influenza virus and COVID-19. The study was published in Nature.
Gilead gets approval for Jyseleca (Filgotinib) in Japan for Rheumatoid Arthritis
Gilead Sciences announced that the Japanese Ministry of Health, Labour and Welfare has granted Gilead KK (Tokyo, Japan) regulatory approval of Jyseleca (filgotinib 200 mg and 100 mg tablets), a once-daily, oral, JAK1 preferential inhibitor for the treatment of rheumatoid arthritis (RA) in patients who have had an inadequate response to conventional therapies, including the prevention of structural joint damage.
Gilead Japan will hold the marketing authorisation of Jyseleca in Japan and will be responsible for product supply of Jyseleca in Japan, while Eisai will be responsible for product distribution of Jyseleca in Japan in RA. The companies will jointly commercialise the medicine to make it available to physicians and patients across Japan.
Curevac links Covid-19 Vaccine to immune response, setting it up to enter pivotal trial
CureVac has shared phase 1/2 data on its COVID-19 vaccine candidate CVnCoV. The German biotech said the mRNA vaccine dose selected for further development sparked increases in virus-neutralizing antibodies and early indications of T-cell activation. While BioNTech and Moderna raced mRNA vaccines into the clinic, CureVac advanced its candidate into human testing more slowly, albeit still at a breakneck speed by historical standards.
CureVac used the extra time in preclinical to design a differentiated asset. Rather than build upon chemical modification of the RNA, CureVac optimized the nucleic acid itself. The result is an mRNA vaccine that CureVac expects to generate a balanced immune response and be more straightforward to scale up. The phase 1 data provide an early, incomplete look at whether the candidate can live up to those expectations.
Global opioid use disorder market to reach $3.7 bn by 2028
The opioid use disorder (OUD) market is expected to grow from $1.6 billion in 2018 to $3.7 billion by 2028 across the eight major markets (8MM) at a compound annual growth rate (CAGR) of 8.8 per cent, according to GlobalData.
The company's latest report, 'Opioid Use Disorder-Opportunity Analysis and Forecasts to 2028', reveals that the main driver of growth will be the launch of reformulations of buprenorphine, in particular extended-release formulations including Indivior's Sublocade and Camurus' Buvidal.
Vivet, Pfizer sign pact for gene therapy to treat Wilson disease
Vivet Therapeutics and Pfizer announced that they have entered into a manufacturing agreement, under which Pfizer will provide clinical supply for a Phase 1/2 clinical trial evaluating Vivet's proprietary, investigational gene therapy, VTX-801, for the potential treatment of Wilson disease, a rare and potentially life-threatening liver disorder. The trial is expected to commence in early 2021. Terms of the agreement were not disclosed.
CURRENT DEVELOPMENTS – INDIA
Pharma sector needs global collaboration
The need of global collaboration in the pharma sector from research and development to drug manufacturing has never been as great as it is now amid the deadly COVID pandemic. Ahead of the 14th edition of the annual BioPharma and Healthcare Summit, that bring stakeholders from India and the United States on one platform, officials and industry leaders said the global health crisis requires a global solution, which can be achieved through global collaboration. It was highlighted that India and the United States can play a lead role in this.
ICRA revises domestic pharma industry outlook to negative
Rating agency ICRA has revised its outlook on Indian pharmaceutical industry to negative from stable due to ongoing lockouts in parts of China following the outbreak of coronavirus. The domestic drug industry is highly dependent on imports, with more than 60 % of its API requirement being shipped from overseas locations, especially China.
In some specific active pharmaceutical ingredients (APIs), like cephalosporins, azithromycin and penicillin, the dependence is as high as 80-90 % of the total imports of APIs and intermediates into India, China accounts for 65-70%.
Indore SEZ exports log marginal decline in Apr-June amid Covid-19 pandemic
Exports from Indore Special Economic Zone (SEZ) have not been impacted much due to the coronavirus outbreak, with outward shipments dropping merely 1.14 per cent in April-June. The multi-product Indore SEZ logged exports worth Rs 2,555.42 crore in the first quarter of the ongoing fiscal as against Rs 2,584.88 crore in the corresponding period a year ago.
In this, 70 per cent contribution was of medicines, according to a union commerce ministry official. Despite the lockdowns imposed due to COVID-19, the production in pharma units continued as the government kept it under essential services category.
UCPMP should be made mandatory without further delay: experts
Recently, D V Sadananda Gowda, Minister of Chemicals and Fertilizers, informed that the Uniform Code for Pharmaceuticals Marketing Practices (UCPMP) is voluntary in nature and the Government has not yet decided to make it mandatory. This announcement did not go down well with patient activists and the medical fraternity.
Extending benefits to doctors through associations is unethical. But this is being flouted with impunity. The Medical Council of India (MCI) had amended the Indian Medical Council (Professional conduct, etiquette and Ethics) regulations, 2002 at its meeting on February 18, 2014, and exempted the "Professional Associations of Doctors" from the purview of Medical Ethics. Industry experts feel there is an urgent need to take steps to reverse this amendment of the MCI and make the UCPMP mandatory.
Govt. regulation may hamper pharma sector growth: Pfizer
Pharma major Pfizer fears that the pharma industry is expected to face challenges due to government regulations. "While implementation of large scale healthcare initiatives expected to provide a boost to the pharma industry, there will be continued challenges in the areas of price controls, ad-hoc regulatory changes and new policies that may impact predictability and sustainable growth," it further said.
PRODUCT APPROVALS / LAUNCHES - INDIAN COMPANIES
DRL launches Dimethyl Fumarate DR capsules in US
Dr Reddy's has launched dimethyl fumarate delayed-release capsules, a therapeutic equivalent generic version of Tecfidera (dimethyl fumarate) delayed-release capsules for Multiple Sclerosis (MS), approved by the USFDA. The Tecfidera brand and generic market had US sales of approximately $3.8 billion MAT for the most recent twelve months ending in June 2020 according to IQVIA Health.
Lupin launches Divalproex Sodium ER Tablets
Lupin announced the launch of divalproex sodium extended-release (ER) tablets USP, 250 mg and 500 mg, having received an approval from the USFDA earlier. Divalproex sodium ER tablets USP is the generic equivalent of depakote extended release (ER) tablets of AbbVie indicated for Acute treatment of manic or mixed episodes associated with bipolar disorder (with or without psychotic features), Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures and Prophylaxis of migraine headaches.
Glenmark launches Nindanib (Nintedanib) for Pulmonary Fibrosis in India
Glenmark Pharma launched NINDANIB (Nintedanib 100 and 150 mg capsules) for the treatment of pulmonary fibrosis in India. Nintedanib is approved by the Indian drug regulator for the treatment of idiopathic (unknown cause) Pulmonary Fibrosis. In a recently published INBUILD trial, Nintedanib showed significantly lower annual rate of decline in FVC (Forced Vital Capacity) – a measure of lung health – with various progressive fibrosing interstitial lung diseases. Moreover, two clinical trials are being rolled out for to study the efficacy and safety of Nintedanib as a treatment of SARS-COV2 induced Pulmonary Fibrosis in moderate to severe COVID-19 patients," informed the company through a statement.
Sun Pharma arm launches Plaque Psoriasis treatment drug in Japan
Sun Pharma's Japanese subsidiary has launched its specialty product Ilumya, indicated for treatment of Plaque Psoriasis in adult patients in Japan. It has got approval from the Japanese government. It is a subcutaneous injection (100 mg Syringe) for the treatment of Plaque Psoriasis in adult patients who have an inadequate response to conventional therapies. It is Sun Pharma's first innovative drug to be launched in the Japanese market.
Zydus Cadila gets nod for Fingolimod caps & Verapamil Hydrochloride injection
Zydus Cadila has received final approval from the USFDA to market Fingolimod Capsules, 0.5 mg (US RLD: Gilenya Capsules). Fingolimod is an immunomodulating drug. It is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of Multiple Sclerosis (MS). The Company has also received the final approval from the USFDA to market Verapamil Hydrochloride Injection USP, 5 mg/2 mL (2.5 mg/mL) and 10 mg/4 mL (2.5 mg/mL), Single-Dose Vials (US RLD: Isoptin Injection). Verapamil injection is used to rapidly or temporarily restore normal heartbeats in people with certain heart rhythm disorders.
Indoco launches Favipiravir 400 mg tablets
Indoco Remedies announced the launch of FEVINDO (Favipiravir) 400 mg tablets in India. Fevindo – 400 is an antiviral drug, effective against the RNA-based influenza virus. The drug has been approved by DCGI in the treatment of COVID-19.
FINANCIAL PERFORMANCE OF SOME KEY PLAYERS
(Source: ET Markets, Moneycontrol, Company Financial Reports)
Nikhil Chopra is the new CEO of JB Chemicals and Pharmaceuticals
The Board of directors of JB Chemicals & Pharmaceuticals appointed Nikhil Chopra as Whole-time Director and Chief Executive Officer of the Company for a period of five years. Earlier, Nikhil Chopra worked as Head-India Business at Cipla. He holds M.Sc. (Organic Chemistry) from Gujarat University. For over two decades, he has spearheaded breakthrough ideas focused on creating greater access to high quality treatment and medicines, and gain a significant competitive advantage over peers, especially in therapies such as respiratory, urology HIV and paediatric care.
Biocon appoints Anupam Jindal as its CFO
Anupam will head the finance function at Biocon and be part of the Executive Leadership Team. He will report into the company's CEO and MD, Siddharth Mittal. Prior to joining Biocon, Jindal worked with the Vedanta Group of companies for 22 years, where he held the position of Group CFO at Sterlite Technologies since 2006. He holds a Bachelor of Commerce (B Com) degree from ML Sukhadia University, Udaipur. He is also a Chartered Accountant from the Institute of Chartered Accountants of India and a Company Secretary.
Vaibhav Karandikar is the new CFO of Sanofi India
Sanofi India announced the appointment of Vaibhav Karandikar as Chief Financial Officer (CFO), effective October 6, 2020. Karandikar joined Sanofi 13 years ago. He is a Chartered Accountant, Cost Accountant & Company Secretary. He has held growing responsibilities in business controlling, accounting and in various M&A and transformation projects, for both commercial operations and manufacturing facilities. Prior to joining Sanofi, Vaibhav has worked with Sandoz India, Tata Power and Hindustan Ciba Geigy.
S Aparna appointed as Secretary, Department of Pharmaceuticals
S Aparna, an IAS officer from the Gujarat cadre 1988, has been appointed as Secretary, Department of Pharmaceuticals (DoP), under the Ministry of Chemicals and Fertilizers. She will succeed PD Vaghela, who demitted the office on his superannuation on September 30, 2020, as per an order issued by the Department of Personnel and Training. In 2017, she was appointed to the post of Executive Director, World Bank, representing the Constituency of India, Bangladesh and Sri Lanka. In 2019, she was given a proforma promotion as Additional Chief Secretary (ACS) while she was on deputation in Washington DC as Executive Director, World Bank.
Manjiri Gharat elected as VP of FIP for 2020 – 2024
Manjiri Gharat, VP & Chairperson, Community Pharmacy Division of Indian Pharmaceutical Association (IPA), has been elected as Vice President of the International Pharmaceutical Federation (FIP) for 2020 – 2024. She is the first woman pharmacy professional and second pharmacy professional from India to be elected as FIP Vice President. In the past, Praful Sheth had been VicePresident of FIP for the term 2006 – 2010 & 2010  2014. The International Pharmaceutical Federation (FIP) is a global body representing over four million pharmacists and pharma scientists.
Zydus wellness appoints Sandeep Anand as its new Chief Marketing Officer
Sandeep Anand was earlier the CMO for the Food Delivery business of Zomato. He focused on Offline marketing (Consumer Advertising), Digital (Performance Marketing, CRM, Growth Analytics, and Alliances. He is an alumnus of Jamia Milia Islamia & Management Development Institute (MDI). Sandeep joined Zomato in December 2018 from GSK Healthcare known for Horlicks. Sandeep has worked with GSK, Ranbaxy, and Reckitt Benckiser in his career.
Alind Sharma joins Optum as Vice President – Human Capital
Optum, a health services and innovation company, has announced the appointment of Alind Sharma as VP – Human Capital. In his earlier role, Alind was with Pfizer as Senior Director in charge of HR responsibilities across all Pfizer manufacturing sites in the APAC region. He has worked with Monsanto, Tata International, Glenmark Pharma and Ranbaxy. He is a Mechanical Engineer and completed his management studies at IIM Ahmedabad.
Indegene hires C-suite Executives from GE & Quikr
Healthcare technology company Indegene has brought on board Marut Setia, former chief marketing officer for GE's South Asia region, as Senior VP-Emerging Markets and Devices. Atul Tewari, former COO of Quikr, has also joined as Senior VP-Global Delivery. Setia was part of the executive leadership team at GE. His main areas of expertise are in incubating new businesses, P&L leadership, business transformation, revenue marketing and finance management. Tewari, in his most recent experience as COO of Quikr, was part of the team that has built India's largest horizontal classifieds with deep vertical focus into real estate, jobs, goods, services and automobiles. Prior to Quikr, he was managing director at BlackRock in Gurugram.
Sridhar Desikan of Dr. Reddy's joins Piramal Pharma Solutions in a global role
Dr. Reddy's Head of Technology Strategy & Innovation, Dr. Sridhar Desikan, has joined Piramal Pharma Solutions as Global Technical Head of Formulations R&D. He will be based in the United States and will lead R&D teams across the globe. Before DRL, he worked with Biocon where he was part of the team to establish Biocon's BMS R&D center. He was also with Dupont Pharma and Novartis as a Research Investigator earlier in his career. He completed his Chemical Engineering from BITS Pilani along with Masters and PhD from the United States.
TALENT INSIGHTS
Indian Pharma industry has always primarily focused on generics as a business model. Some companies have tried to go the innovation route but it has yielded limited results. The pipeline of new molecules has come down, thereby reducing opportunities in generics.
COVID-19 has led to an increased demand for Digital Transformation and Manufacturing professionals. In addition, with new product launches being postponed, Life Cycle Management (LCM) is a major area where increasing number of companies are focusing.
Top areas where we are seeing an increased talent demand are the following:
Scaling up is one of the major areas where talent is needed and a lot of companies are gearing up for the challenge.
Technology and Digital Transformation
COVID-19 has spurred a sharp rise in demand for specialists with expertise in new-age technologies along with cross functional experience in Pharma.
Analytics is here to stay and more and more industries are implementing it in their plans. This holds true for both Product Development and Marketing/Sales Force Effectiveness.
Regulatory and Govt Affairs
With the pricing pressure likely to continue for next few quarters, this is a strong area that has emerged and many companies are strengthening their expertise.
Business Development/Licensing
With the generics market not giving the right growth, companies are moving towards collaborations and licensing opportunities. Deal makers in this area are in high demand.
Medical Affairs and Real World Evidence
This is another area that is seeing an uptrend given the importance of Real World Evidence and HEOR.
With the digital boom, Marketing is seeing an overhaul and is seeing a dynamic shift. Companies are increasingly focusing on newer ways to maximize their marketing and outreach.
EMA Partners – Research Team
Fierce Pharma News
World Pharma News
European Pharmaceutical Review
Express Pharma News
ET Markets & ET Prime
Company Annual Reports
Disclaimer: The information presented has been obtained through multiple sources including those provided in the bibliography section and is subject to change/validation. While every effort has been made to ensure the accuracy of the information provided, EMA Partners does not explicitly guarantee the accuracy of the information. EMA Partners does not accept any liability for any decisions made on the basis of the information provided.
The Importance of Executive Search for Venture Capital Funds
The Adaptive Leader in a VUCA Environment - Pre and post the COVID-19 Pandemic
Navigating Through The New World of Digital - A Virtual Reality
Copyright @ 2020 EMA Partners
'); // $this.css('width', widthGet+"px"); // } } }); } changeAnimation(); /* Start Animation */ $(document).on('click',".filter-button",function(){ var value = $(this).attr('data-filter'); $(".filter-button").removeClass("active"); $(this).addClass("active"); if(value == "all") { $('.filter').show('1000'); } else { $(".filter").not('.'+value).hide('3000'); $('.filter').filter('.'+value).show('3000'); } }); //$('.filter-button[data-filter="category1"]').trigger('click'); new WOW().init(); });